Sippican Capital Advisors Sells 46,929 Shares of Pfizer Inc. (NYSE:PFE)

Sippican Capital Advisors lowered its stake in Pfizer Inc. (NYSE:PFE) by 53.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,397 shares of the biopharmaceutical company’s stock after selling 46,929 shares during the quarter. Sippican Capital Advisors’ holdings in Pfizer were worth $1,098,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer in the 4th quarter valued at approximately $26,000. Gladius Capital Management LP increased its holdings in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Quarry LP bought a new position in shares of Pfizer in the 2nd quarter valued at $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer during the 3rd quarter valued at $35,000. Finally, Joseph Group Capital Management grew its position in Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $26.65 on Thursday. The firm has a market cap of $151.00 billion, a PE ratio of 36.01, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The business’s 50 day moving average price is $26.18 and its two-hundred day moving average price is $27.91. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the company earned ($0.17) EPS. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.46%. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Guggenheim cut their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday. Finally, Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.